Steven Chance for Oxford Brain Diagnostics, Ltd

Oxford Brain Diagnostics Ltd

Founded in neuropathological and neuroimaging expertise, the company’s patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases. The CDM® software device can be used as an adjunct to other diagnostics evaluations, intended to predict conversion from Mild Cognitive Impairment to Alzheimer’s Disease in patients previously diagnosed with MCI.

Other Presentations

Aevum – Gail Chan, PhD – View

 

AKScientist – Aarti Kuver, PhD – View

 

AmyloiDia – Vladana Vukojevic, PhD View

 

ASDERA LLC – Knut Wittkowski, PhD – View

 

BIORCHESTRA Co., Ltd – Branden Ryu, PhD – View

 

BioTrillion, Inc. – Savan Devani, MS – View

 

BrainCures – Krzysztof Potempa, PhD – View

 

BrainTrip – Jurij Dreo, MD – View

 

Diadem – Simona Piccirella, PhD – View

 

Generian Pharmaceuticals, Inc. – Toren Finkel, MD, PhD – View

 

Lauren Sciences LLC – Susan Rosenbaum, JD –View

 

LumeNeuro – Ron Dennis – View

 

Marvel Biotechnology – Mark Williams, PhD, MBA – View

 

Memandis – Nareem Surya View

 

MGH/Harvard Medical School – Xudong Huang, PhD – View

 

Neuropath Therapeutics Limited – Julie Kelly, PhD – View

 

University of Haifa – Nathaniel Gould, PhD – View

 

Winterlight Labs – Nicola Johnson, MS – View